Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Amazon Biotech obtains financing for phase II HIV trials
“This financing brings us a long way toward meeting our funding goals and putting us in position to go forward with our phase II trials upon receipt of
“This financing brings us a long way toward meeting our funding goals and putting us in position to go forward with our phase II trials upon receipt of
VaxGen announced in May 2005 that it would fund proof-of-concept studies and then determine whether to pursue commercial development of the vaccine candidate. The initial proof-of-concept phase was
The acceptance period is now extended to June 14th; however Bayer warned that no further extension would be possible. “The extension of the acceptance period enables all Schering
Barr is likely to face competition for the capture of Pliva, eastern Europe’s biggest drug maker, as the entire generics industry heads towards greater consolidation. After having an
Vical retains exclusive marketing rights for the drug in the US and the rest of the world outside of specified Asian countries, for which AnGes received exclusive rights.
Biogen Idec licensed the exclusive worldwide rights to develop and market BG-12 from Swiss based privately held pharmaceutical company Fumapharm. The study achieved its primary endpoint, demonstrating that
This clinical trial is designed to assess the safety and efficacy of velafermin for the prevention of oral mucositis in cancer patients receiving high-dose chemotherapy, with or without
The “cooperative research and development agreement” (CRADA) will provide Lentigen with access to Edgewood Chemical Biological Center's (ECBC) manufacturing facilities and services. Financial terms of the deal were
A twice-daily formulation of Xibrom has already been approved by the FDA for the indication. The Xibrom once-daily phase III clinical trials are expected to enroll approximately 350
The trial is being conducted by Cancer and Leukemia Group B (CALGB), an oncology clinical research group sponsored by the National Cancer Institute (NCI). LE-SN38 is NeoPharm's NeoLipid